This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. NNVC, HILS, IBIO, TAOX, AEON, OBSV, AEZS, SPRB, NRBO, and CPHIShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include NanoViricides (NNVC), Hillstream BioPharma (HILS), iBio (IBIO), Synaptogenix (TAOX), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), Spruce Biosciences (SPRB), NeuroBo Pharmaceuticals (NRBO), and China Pharma (CPHI). Gemphire Therapeutics vs. Its Competitors NanoViricides Hillstream BioPharma iBio Synaptogenix AEON Biopharma ObsEva Aeterna Zentaris Spruce Biosciences NeuroBo Pharmaceuticals China Pharma Gemphire Therapeutics (NASDAQ:GEMP) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Which has higher earnings and valuation, GEMP or NNVC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemphire TherapeuticsN/AN/A-$23.64MN/AN/ANanoViricidesN/AN/A-$8.29M-$0.70-2.26 Does the media prefer GEMP or NNVC? In the previous week, Gemphire Therapeutics' average media sentiment score of 0.00 equaled NanoViricides'average media sentiment score. Company Overall Sentiment Gemphire Therapeutics Neutral NanoViricides Neutral Which has more volatility & risk, GEMP or NNVC? Gemphire Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Is GEMP or NNVC more profitable? NanoViricides' return on equity of -87.90% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemphire TherapeuticsN/A -419.70% -173.05% NanoViricides N/A -87.90%-78.69% Do institutionals and insiders have more ownership in GEMP or NNVC? 17.5% of Gemphire Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 22.7% of Gemphire Therapeutics shares are held by insiders. Comparatively, 4.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryGemphire Therapeutics and NanoViricides tied by winning 3 of the 6 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.37M$782.52M$5.50B$9.72BDividend YieldN/A4.84%4.59%4.12%P/E RatioN/A1.1830.0524.70Price / SalesN/A25.58456.53100.55Price / CashN/A19.5624.8428.01Price / Book1.176.548.525.76Net Income-$23.64M-$4.11M$3.27B$267.05M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.63-1.0%N/A-82.5%$9.37MN/A0.009Gap DownNNVCNanoViricides0.2999 of 5 stars$1.58-0.6%N/A-16.4%$25.39MN/A-2.1920HILSHillstream BioPharmaN/A$1.24-0.4%N/A-57.8%$21.83MN/A-1.721IBIOiBio1.1283 of 5 stars$0.62-1.6%$5.00+702.7%-61.9%$10.29M$375K0.00100TAOXSynaptogenixN/A$5.89-9.2%N/AN/A$9.02MN/A0.004Gap DownAEONAEON Biopharma3.3593 of 5 stars$0.73+1.6%$360.00+48,919.6%-99.1%$8.30MN/A4.085News CoverageUpcoming EarningsOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050Gap UpAEZSAeterna ZentarisN/A$3.82-2.1%N/A-37.2%$6.85M$2.37M-0.2620Upcoming EarningsGap UpSPRBSpruce Biosciences1.9812 of 5 stars$0.14+12.5%$131.25+97,122.2%-69.6%$5.70M$4.91M-0.1420News CoverageNegative NewsUpcoming EarningsGap DownNRBONeuroBo PharmaceuticalsN/A$0.60-2.1%N/A-82.5%$5.14MN/A0.0010Upcoming EarningsGap UpHigh Trading VolumeCPHIChina PharmaN/A$1.56-2.5%N/A-91.6%$5.09M$4.30M0.00250 Related Companies and Tools Related Companies NanoViricides Competitors Hillstream BioPharma Competitors iBio Competitors Synaptogenix Competitors AEON Biopharma Competitors ObsEva Competitors Aeterna Zentaris Competitors Spruce Biosciences Competitors NeuroBo Pharmaceuticals Competitors China Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
